3 stories mentioning SHA:603087Updated 38d ago
Every FINWIRES story that references SHA:603087, newest first.
The European Commission granted Gan & Lee Pharmaceuticals (SHA:603087) marketing authorization for insulin aspart injection Dazparda, according to a Shanghai bourse filing on Thursday.The Chinese pharmaceutical company's unit, Gan & Lee Pharmaceuticals Europe, is the authorized marketer of the product in Europe.The company's shares rose 1% at the close.
Gan & Lee Pharmaceuticals (SHA:603087) received approval from China's National Medical Products Administration for the clinical trials of GLR1062 injection, according to a Shanghai bourse filing on Thursday.The drug will be tested for the treatment of neovascular (wet) age-related macular degeneration in adults.
Gan & Lee Pharmaceuticals' (SHA:603087) subsidiary, Gan & Lee Pharmaceuticals Shandong, dosed the first subject for the phase III clinical trial of GZR33 injection, according to a Shanghai bourse filing on Wednesday.The drug is being tested as a treatment for type 2 diabetes.The pharmaceutical company's shares rose less than 3% during the afternoon trade.
